The ingredient development firm announced the new approval recently. The official imprimatur through Agencia Nacional de Vigilancia Sanitaria (ANVISA) not only opens up the Brazilian market, but gets a foot in the door for the use of myHMB in healthy aging products in other markets in Latin America as well, according to Larry Kolb, co founder and president of TSI.
TSI Group brought the original ingredient developer, Metabolic Technologies Inc., fully within house more than a year ago.
Metabolic Technologies, based in Ames, IA, is a spinoff technology company from Iowa State University. The company was built around the discovery of the ingredient. The strategic acquisition integrates TSI’s HMB production and global sales and business development capabilities with MTI’s intellectual property portfolio and clinical research and development strengths.
Research history backs ingredient
HMB was first discovered by MTI in the early 1990s. It has long been popular among sport nutrition brands for its strength, recovery and improved body composition benefits for highly trained and competitive athletes. But lately TSI has been spreading the word about an expanding and body of evidence that shows HMB provides muscle health benefits to a much larger base of consumers beyond traditional sports nutrition.
HMB, or β-hydroxy β-methylbutyrate, is naturally produced in the body during the metabolism of the essential amino acid leucine, which is found in virtually all protein sources. TSI co founder and president Larry Kolb said research done on myHMB, the company’s branded, nature identical form of the substance, has shown that HMB supplementation can lead to beneficial results. In a study done on judo competitors and wrestlers the researchers concluded that, “The results indicate that supplying HMB promotes advantageous changes in body composition and stimulates an increase in aerobic capacity.”